Study of the Mechanisms of Metabolic Adaptations to Overfeeding

Overview

Obesity results from complex interactions between genetic and environmental factors, and are strongly associated with metabolic complications such as type 2 diabetes mellitus. Obesity is defined as an excessive fat accumulation that presents a risk to health, a risk that is highly dependent upon the type of adipose tissue accumulation, whether visceral or sub-cutaneous, but also upon the characteristics of the fat tissue, especially inflammatory cells accumulation. Because of the well known sexual difference in fat accretion, this obesity-associated risk may also be very different for men and for women. In addition, recent data indicate that various factors such as the intestinal microbiota, but also the dietary intake of protective nutrients might be important determinants of the metabolic complications of obesity. Here we propose to: 1) study the metabolic adaptations and the mechanisms of adipose tissue accumulation during a period of controlled caloric over-nutrition, both in men and in women; 2) evaluate the potential protective effects of a supplementation with polyphenols on insulin resistance and other metabolic adaptations.

Full Title of Study: “Study of the Determinants and Mechanisms of Adaptation of Metabolic Responses to Controlled Overfeeding in Female and Male Healthy Volunteers”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Basic Science
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: May 2016

Detailed Description

To achieve these goals, healthy male and female volunteers will be enrolled into a one month longitudinal, prospective study on the influence of hypercaloric overfeeding (+50% of daily caloric needs) on different tissues (adipose tissue, muscle and blood). They will be separated into two different groups: hypercaloric nutrition and placebo, and hypercaloric nutrition and polyphenols (2g/day), where polyphenols administration will be randomized and administered in a double blind fashion. Whole body and hepatic insulin sensitivity, total energy expenditure, glucose hepatic production, protein and gene expression in muscle, adipose tissue and blood as well as intestinal microbiota will be assessed at base line, and after one month of overfeeding.

Interventions

  • Other: Hypercaloric diet
    • Hypercaloric diet will be designed to provide 50% excess in calories compared to daily requirements. It will consist in a “snack” type, high fat and high carbohydrates diet.
  • Dietary Supplement: polyphenols
    • Administration of polyphenols will consist in the administration of 1 gram (5×200 mg) of the compound bid during the entire overfeeding period.
  • Dietary Supplement: placebo (for polyphenols)
    • Placebo will consist in the administration of a number of placebo pills matching that of polyphenols, in a similar way (bid) for the duration of the overfeeding experiment.

Arms, Groups and Cohorts

  • Experimental: Hypercaloric diet and polyphenols
    • polyphenols will consist in the administration of 1 gram (5×200 mg) of the compound bid during the entire overfeeding period. Hypercaloric diet will consist in a hypercaloric diet providing an excess of 50% KCal over daily requirements, and will last 30 days.
  • Active Comparator: Hypercaloric diet and placebo
    • Placebo will consist in the administration of a number of placebo pills matching that of polyphenols, in a similar way (bid) for the duration of the overfeeding experiment. Overfeeding will consist in a hypercaloric diet providing an excess of 50% KCal over daily requirements, and will last 30 days.

Clinical Trial Outcome Measures

Primary Measures

  • Change from baseline in insulin sensitivity
    • Time Frame: baseline, day 31 of overfeeding
    • Whole body insulin sensitivity will be measured during hyperinsulinemic, euglycemic clamps.

Secondary Measures

  • Change from baseline in muscle and adipose tissue gene expression
    • Time Frame: Baseline, day 28 of overfeeding
    • Transcriptomic experiments will be performed on muscle and adipose tissue samples

Participating in This Clinical Trial

Inclusion Criteria

  • normal healthy male and female volunteer Exclusion Criteria:

  • Diabetes mellitus – High blood pressure – Liver disease – Kidney disease

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: 30 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Centre Hospitalier Universitaire Vaudois
  • Collaborator
    • University of Lyon
  • Provider of Information About this Clinical Study
    • Principal Investigator: Francois Pralong, Full Professor and Head, Cervice of Endocrinology, Diabetology and Metabolism – Centre Hospitalier Universitaire Vaudois
  • Overall Official(s)
    • Francois P Pralong, MD, Principal Investigator, Centre Hospitalier Universitaire Vaudois
  • Overall Contact(s)
    • François P Pralong, MD, +41 21 314 0596, Francois.Pralong@chuv.ch

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.